Following live discussions with health-care providers about their experiences with Omnipod 5 at the American Diabetes Association (ADA) Conference 2025, Within Range hosts Kate Neal and Cindy Pickering reflect on how automated insulin delivery systems provide discretion and comfort, empowering patients in their diabetes care and improving outcomes after diagnosis.
We hear touching stories including one about a teenage girl finally embracing her diagnosis thanks to advancements in diabetes technology, as well as stories of children and adults improving their quality of life thanks to automated insulin delivery.
Who you’ll hear from on this episode of Within Range:
- Dr DeSalvo – Paediatric endocrinologist sharing real-world success stories, focusing on easing the diabetes burden for teenagers and enhancing quality of life with Omnipod 5.
- Dr Aleppo – Diabetes specialist discussing the comprehensive evidence behind offering automated insulin delivery systems to a broader range of patients, emphasising the importance of awareness and education.
- Dr Zahareva – PhD and diabetes educator offering insights on optimal use of Omnipod 5 during exercise.
The experts in this episode discuss:
- The challenges teenagers face in diabetes management, the impact of Omnipod 5 on improving glycemic management, and fostering healthier social relationships.
- Insights from leading health-care professionals on starting patients on Omnipod 5, customising settings, and the importance of education and appropriate adjustments in system settings.
- Findings from the Radiant Study highlighting transitions from multiple daily injections of insulin (MDI) to Omnipod 5, showcasing improvements in HbA1c levels and overall diabetes management.
- The consensus on using automated insulin delivery systems with exercise, emphasising the role of balanced carbohydrate intake and pre-exercise system settings.
Note: The information in this podcast is accurate to the date of recording as of 06/23/2025. All HCPs interviewed received a fee from Insulet for taking part in this Podcast, views and opinions of these HCPs expressed in this podcast are their own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.
Note about some clinical claims throughout this episode:
Berget Claims: 110mg/dL Glucose Target does not increase hypoglycemia
1. Claim-000433: Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Real-world data from 403 people with type 1 diabetes aged 2+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range (70-180 mg/dL) improved 11.8% (p<0.05). Median time <70 mg/dL +0.23% (p<0.05). Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Data on File. 05.15.25. RF-042025-00013
DeSalvo Claims: Adolescents improve TIR and experience less diabetes distress
2. Brown S. et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%. Study funded by Insulet.
3. Hood K. et al. Pediatr Diabetes (2023). Prospective pivotal trial including 42 adolescent participants with T1D aged 12-17.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Adolescents experienced reduced diabetes distress (PAID-T) 30.5 vs. 27.1 (P=0.045).
Aleppo: RADIANT improved A1c and TIR (something about hypoglycemia)
4. Claim-000498: Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. HbA1c 13-weeks: control group 8% vs. Omnipod 5 group 7.2% (p<0.0001). TIR 13-weeks: control group 43% vs. Omnipod 5 group 65% (p<0.0001). TBR (<70 mg/dL or 3.9mmol/L) at 13-weeks: non-inferiority was met with 2.56% TBR with Omnipod 5. Data on File. Mar 14, 2025. RF-042025-00015
Exercise Paper: Reduce meal bolus if exercising 1-2 hours after (Othmar) – reference paper here
5. Moser O, Zaharieva DP, Adolfsson P, et al. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia. 2025;68(2):255-280. doi:10.1007/s00125-024-06308-z
INS-OHS-09-2025-00381 v2.0
